Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1099-1101

  Santoni, M ^a   Paccapelo, A ^a   Burattini, L ^a   Onofri, A ^a   Cascinu, S ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Fotemustine (ftm); Glioblastoma; Glioblastoma (gbm); Temozolomide (tmz)

Indexed keywords

FOTEMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 84858771224     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. 6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10: 831-838, 1999.
2. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD and Grever MR: Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res 54: 3793-3799, 1994.
3. Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K and Schold C: Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1 nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium trial. Cancer 100: 1712-1716, 2004.
4. Gaviani P, Salmaggi A and Silvani A: Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neurooncol 104: 617-618, 2011.
5. Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J and Fine RL: Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112: 1139-1146, 2008. (Pubitemid 351304600)
6. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
7. Macdonald DR, Cascino TL, Schold SC Jr. and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990. (Pubitemid 20195640)